0000000000798494
AUTHOR
M. Anselmo
Sur les Codes ZigZag et Leur Décidabilité
AbstractThis paper deals with zigzag factorizations and zigzag codes. The language of “zigzag” over a regular language is represented by constructing a special family of two-way automata. Decidability of zigzag codes, previously shown for the finite languages, is proved here for all regular languages by the analysis of the set of “crossing sequences” produced by a two-way automation in the family. We also obtain that it is decidable whether or not a two-way automation of a certain type is non-ambiguous.RésuméDans ce papier on reprend les notions de factorisation zigzag et de code zigzag. On construit pour tout langage rationnel, une famille d'automates bilatéres lesquels reconnaissent les m…
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing
Abstract Background Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. Methods A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46…
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data
OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…